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Abstract
Introduction: Many countries ravaged by conflict have substantial morbidity and mortality attributed to HIV/AIDS yet 
HIV treatment is uncommonly available. Universal access to HIV care cannot be achieved unless the needs of 
populations in conflict-affected areas are addressed.
Methods: From 2003 Médecins Sans Frontières introduced HIV care, including antiretroviral therapy, into 24 
programmes in conflict or post-conflict settings, mainly in sub-Saharan Africa. HIV care and treatment activities were 
usually integrated within other medical activities. Project data collected in the Fuchia software system were analysed 
and outcomes compared with ART-LINC data. Programme reports and other relevant documents and interviews with 
local and headquarters staff were used to develop lessons learned.
Results: In the 22 programmes where ART was initiated, more than 10,500 people were diagnosed with HIV and 
received medical care, and 4555 commenced antiretroviral therapy, including 348 children. Complete data were 
available for adults in 20 programmes (n = 4145). At analysis, 2645 (64%) remained on ART, 422 (10%) had died, 466 
(11%) lost to follow-up, 417 (10%) transferred to another programme, and 195 (5%) had an unclear outcome. Median 
12-month mortality and loss to follow-up were 9% and 11% respectively, and median 6-month CD4 gain was 129 cells/
mm 3.
Patient outcomes on treatment were comparable to those in stable resource-limited settings, and individuals and 
communities obtained significant benefits from access to HIV treatment. Programme disruption through instability was 
uncommon with only one program experiencing interruption to services, and programs were adapted to allow for 
disruption and population movements. Integration of HIV activities strengthened other health activities contributing 
to health benefits for all victims of conflict and increasing the potential sustainability for implemented activities.
Conclusions: With commitment, simplified treatment and monitoring, and adaptations for potential instability, HIV 
treatment can be feasibly and effectively provided in conflict or post-conflict settings.
Introduction
Many countries ravaged by current or recent conflict
have substantial morbidity and mortality attributed to
HIV/AIDS [1]. Sub-Saharan Africa, with the world's high-
est burden of conflict, is home to around 70% of HIV-
infected people and has the largest unmet need for anti-
retroviral treatment (ART), estimated at around 5 mil-
lion[2,3]. One analysis of HIV treatment in conflict-
affected regions of northern Uganda found access
extremely limited, particularly in remote and rural areas
[4].
Conflict carries with it factors that can worsen the
severity and progression of HIV disease such as food
insecurity, contaminated water supplies, physical and
psychological stress, and higher rates of other infectious
diseases. Furthermore, while there is conflicting evidence
on the issue [1], post-conflict, and to a lesser extent, con-
flict situations may increase susceptibility to HIV trans-
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mission [5]. ART can both significantly reduce HIV
related mortality and morbidity [6] and potentially
reduce HIV transmission [7]. However, despite increasing
access to life-saving ART in more stable environments,
these treatments have been uncommonly available in
conflict or post-conflict settings [5,8].
Reasons for the relative neglect of conflict settings
include: limited access to affected populations; poor
health infrastructure and resources; a lack of prioritiza-
tion of HIV-related health needs given limited resources
and competing medical priorities; recommendations
against providing ART in current international guidelines
for health care in these environments[9,10]; a fear of the
complexity of HIV treatment and lack of relevant guide-
lines and examples to follow; the unstable nature of the
situation leading to concerns about interrupting treat-
ment leading to antiviral resistance; and a belief that
unless the provision of ART can be maintained lifelong
then ART should not be initiated[8]. Nevertheless, it has
been demonstrated that HIV treatment in conflict set-
tings is both feasible and effective [11-14] and guidelines
have been produced[15].
The international aim of universal access to HIV care
[16] cannot be achieved unless the needs of populations
in conflict-affected areas are addressed. As treatment
access increases, ever larger numbers of people on ART
in currently stable areas are at risk of treatment disrup-
t i o n  i f  c o n f l i c t  a f f e c t s  h e a l t h  s e r v i c e s  o r  f o r c e s  t h e i r
migration. Therefore there has been a call to increase
access to HIV treatment and prevention in these settings
[8,17].
Médecins Sans Frontières (MSF) is a humanitarian
organization providing medical care to populations in
crisis. MSF works in many conflict-affected settings
responding to the acute health needs of affected popula-
tions amidst the breakdown of health services (Figures 1,
2, 3). In many of these programmes, urgent and consider-
able HIV-related health needs have been identified. Since
provision of ART could significantly reduce mortality and
morbidity, the MSF operational section of Amsterdam
(MSF-OCA) began to introduce HIV care and treatment
activities into these programmes.
An HIV programme was initiated in Bukavu, a conflict-
affected region of eastern Democratic Republic of Congo
(DRC) in October 2003 and expanded to 24 basic health-
care programmes in 12 countries (Figure 4). We describe
the contexts, activities, outcomes, challenges, and lessons
learned from these programmes, including answers to
common issues raised about potential difficulties in
implementing such programmes. Our aim is to share the
knowledge and experience obtained by MSF and its coun-
terparts and to facilitate and advocate increased commit-
ment for provision of HIV treatment in these settings.
Methods
Programme contexts
We define a conflict setting as one with active intrastate
or interstate conflict. A post-conflict setting is defined as
one within 2 years of a peace agreement being signed and
adhered to between warring parties where often there has
been only a minimal return of populations and function-
ing of health services due to ongoing or potential instabil-
ity.
Additional file 1, Table S1 shows programme contexts
and settings. 22 programmes were in sub-Saharan Africa.
Thirteen were classed as conflict and eleven as post-con-
flict. Most (21) were in rural locations including two in
refugee camps. Most countries had endured decades of
instability, with conflicts lasting an average of 18 years;
MSF had typically been present for 17 years. Additional
file 1, Table S1 shows estimated WHO/UNAIDS country
Figure 1 An MSF clinic in Kabo, Central African Republic, 2007; 
with a sign indicating "no guns allowed in the clinic". Copyright 
Spencer Platt/Getty Images.
Figure 2 Loulambo, Pool region, Republic of Congo, 2003; a ma-
ternity ward destroyed by conflict. Copyright Patrick Deschamps/
MSF.O'Brien et al. Conflict and Health 2010, 4:12
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HIV prevalence data for 2005. Most countries were in
Central and West Africa where prevalence is low to
medium (1-10%) compared with higher rates in more sta-
ble southern Africa (10-50%) [18]. However, these rates
usually reflect the situation in urban and stable areas
where testing has been performed. In many of the areas
where our HIV programmes were introduced there had
been no prior HIV testing. ART coverage rates varied
from 1% in Sudan to 51% in Uganda [see Additional file 1,
Table S1] [19], but considerable in-country variation
exists with rates as low as 2-122 per 1000 of eligible indi-
viduals receiving ART in conflict-affected regions of
northern Uganda [4].
Design of the HIV programmes
The aim was to treat patients attending health facilities
supported by MSF, rather than to comprehensively
address the HIV epidemic in programme areas. There-
fore, programmes focused on patients presenting to the
health facilities with an increased likelihood of having
HIV or where knowledge of HIV status affected medical
care. This included medical inpatients, children in thera-
peutic feeding centres not responding to treatment, preg-
nant women, and patients with tuberculosis, sexually
transmitted infections, or illnesses suggestive of HIV
such as severe candidiasis [see Additional file 2, Table S2].
Here we describe aspects of the programmes focusing on
those important in conflict settings.
Integration of programmes
HIV services were integrated as much as possible into
existing health facilities and activities, apart from Bukavu
in DRC and Malange in Angola which, being the earliest
conflict affected programmes, commenced when MSF
HIV programming had a purely vertical approach. Most
programmes attempted to work with national AIDS pro-
grammes, recognising the eventual need to handover
patients. This ranged from discussions and agreements
with Ministry of Health (MoH) at national level, to full
integration with MoH staff and protocols in clinics and
use of MoH drug supplies.
Diagnostic and treatment protocols
HIV testing was initially offered using the client-initiated
model, but with the focus on providing care to those in
medical need, this approach shifted from 2005 to a pro-
vider-initiated testing model[20]. Two parallel HIV rapid
diagnostic tests (usually Determine HIV-1/2® and Uni-
Gold HIV® ) were used; to facilitate integration with MoH,
occasionally serial testing was implemented (eg Burundi).
Confirmation testing with Orgenics Immunocomb
Combfirm® HIV test was introduced from 2006[21]. For
ART, generic drugs were used in fixed-dose combina-
tions. Eligibility criteria for ART and first-line regimens
were standardised and based on WHO recommenda-
tions.[22]
Human resources
To initiate HIV activities additional human resources
were usually introduced - clinical, counselling, or labora-
tory staff - often supported by temporary expatriate staff
with HIV experience to set up systems and training [12].
The HIV component was only part of an individual's
workload. Doctors caring for patients with HIV would
also work in general inpatient wards, maternity, and
tuberculosis services; HIV counsellors often worked in
psychosocial counselling; and nurses on general medical
wards. Clinical consultations were performed by doctors
or nurses, though an emphasis was placed on task shifting
with nurses often involved in ART care, and community
Figure 3 An MSF car in conflict-affected northern Uganda. Copy-
right Keith Philip Lepor.
Figure 4 Map showing programme sites in Africa.* Sites in Ma-
nipur, India; and Sincelejo, Colombia not included.O'Brien et al. Conflict and Health 2010, 4:12
http://www.conflictandhealth.com/content/4/1/12
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health workers or patients involved in HIV counselling
and adherence training.
Monitoring and data collection
Monitoring was clinical, supported in most projects by a
limited range of labora tory investigations such as CD4
counts and liver function tests [see Additional file 1,
Table S1]. Often programmes began with clinical moni-
toring, and laboratory investigations were introduced
later. Data collection and programme monitoring usually
utilized standardised FUCHIA software (Epicentre,
P a r i s ) .  D a t a  w e r e  c o l l e c t e d  a t  e a c h  c o n s u l t a t i o n  u s i n g
standardised forms and entered centrally into an elec-
tronic database by dedicated clinicians or clerical staff.
Enrolments, survival, defaulter rates, tuberculosis rates
and treatment, and immunological status on ART were
regularly monitored using standardised MSF HIV indica-
tors.
Sexual violence
All programmes had a gender-based violence component,
including treatment for sexually-transmitted infections,
emergency contraception, counselling, and access to HIV
post-exposure prophylaxis (PEP). Although knowledge of
HIV status is desirable, to avoid further stress to rape vic-
tims and delays, post-exposure prophylaxis was generally
given before HIV counselling and testing, which was
organized within the subsequent few days. The rationale
was that a few days of antiretroviral drugs for an HIV-
positive person would not promote anti-viral resistance,
especially as non-nucleoside reverse transcriptase inhibi-
tor (NNRTI)-based regimens were not used. Most vic-
tims presented for care after the minimum time for PEP
(<72 hours), often months to years after the event.
Contingency planning
Contingency plans covered a variety of scenarios, from
complete long-term evacuation of the programme, to
short-term partial breaks in care delivery. Staff and
patients were prepared for evacuation of staff, reduction
of medical activities, limitations of movement, break-
down of usual communication systems, and looting.
P a t i e n t s  w e r e  p r e p a r e d  t o  c o p e  w i t h  f o r c e d  d i s p l a c e -
ments, limitation of movement, and rupture of personal
medical stocks. Detailed descriptions of contingency
planning have been reported [11,12,23,24] and are sum-
marised and updated in appendix 1.
Data analysis
Data were analysed using automated reports available in
FUCHIA software (v1.6.2.526) through the R pro-
gramme, which provide patient outcomes by month or by
time in ART cohorts. Detailed patient data were exported
from FUCHIA according to time on AR T cohorts and
analysed further using Microsoft® Office Excel® 2007 and
STATA 10.0 (StataCorp, Texas).
Results
Programme outcomes
Additional file 2, Tables S2 and S3 show programme data
and outcomes. More than 10 500 people were diagnosed
HIV-positive and received medical care. Median overall
HIV prevalence in tested patients was 12% (range 2-45%)
and was as high as 78% in tuberculosis patients (median
13%, range 4-78%). A comparison of MSF antenatal clinic
data with WHO/UNAIDS 2005 national HIV prevalence
estimates[18] showed that HIV prevalence was generally
lower than expected - e.g. Shabunda, DRC (1% vs 2-5%),
Boguila, Central African Republic (1% vs 6-7%), and Dan-
ane, Cote D'Ivoire (3% vs 5-10%). This may result from
limited population movement and mixing in conflict-
affected regions and is consistent with research that sug-
gests conflict may limit HIV transmission [1].
In the 22 programmes where ART was initiated, 4555
(43%) HIV-positive individuals started ART, including
348 children ( < 15 years). Follow-up information was
incomplete in two programmes, and the numbers of chil-
dren on ART were too small to make robust conclusions.
Therefore, analyses were restricted to adults in the
remaining 20 programmes (n = 4145). Of these, by the
time of analysis, 2645 (64%) remained on ART in the pro-
gramme, 422 (10%) had died, 466 (11%) lost to follow-up,
417 (10%) transferred to another programme, and 195
(5%) had an unclear outcome [see Additional file 2, Table
S2].
More detailed further analysis was performed for adults
in 12 programmes [see Additional file 2, Table S3], lim-
ited by not having complete data for all programmes due
to either loss of Fuchia data post-closure (2 projects) or
because Fuchia was not implemented (8 projects). ART
baseline data revealed patients that were young (median
age 35 years), predominately female (median 66%),
severely immunosuppressed (median proportion WHO
stage 3/4 80% and median baseline CD4 139 cells/mm 3),
and ART-naïve (median 94%). For the 2572 (61%) adults
with 12-month data, median 12-month survival was 0.89
(95% CI 0.88-0.91) and proportion lost to follow-up was
0.11 (95% CI 0.09-0.12) [see Additional file 2, Table S3].
In addition, robust immunological gains were achieved in
our cohorts with median 6-month CD4 gain of 129 cells/
mm 3. Median follow-up time on ART was 11.8 months
(IQR 3.9-22.7).
Discussion and Evaluation
Many obstacles have contributed to the lack of ART pro-
grams in conflict or post-conflict affected areas. They
include issues related to health need prioritisation, feasi-
bility, effectiveness, safety and ethics. Our study provides
important information that can be useful in addressing
many of these concerns.O'Brien et al. Conflict and Health 2010, 4:12
http://www.conflictandhealth.com/content/4/1/12
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1. "HIV treatment is complex. It will not be possible to 
assure safe and effective treatment in conflict affected 
settings."
Experience from vertical HIV programmes in resource-
limited settings has led to simplification of treatment
with standardised treatment protocols, fixed-dose com-
bination drug regimens, minimal monitoring, and inten-
sive adherence support. This approach has proved safe
and effective [25] and can be applied without major
changes in conflict settings. In our programmes, fixed-
dose combinations facilitated adherence, procurement,
and stock management, and reduced costs. Relatively
complex monitoring tools such as CD4 counts and liver
function tests allowed a paradoxical simplification of
management and increased the ease of decision making
by less experienced clinical staff [12]. HIV activities were
introduced in a stepwise manner that avoided over-
whelming teams and allowed staff time to gain experience
in HIV care and systems to be put in place.
The evidence presented here and previously from our
programmes and from others suggests that ART out-
comes are equivalent to those in stable resource-limited
settings [11-14]. In this study, the median 12-month sur-
vival of 0.89 (0.88-0.91) compares favourably with that in
Malawi (0.81;0.79-0.83),[26] Zambia (0.82) [27] and
South Africa (0.93;0.92-0.94) [28]. In addition, it is com-
parable with the ART-LINC study, to date the largest
combined analysis of cohorts in stable resource-limited
settings;[29] mortality in our programmes (9% versus
ART-LINC 6%) and lost-to follow-up rates (11% versus
ART-LINC 15%) after 12 months of treatment, as well as
median immunological gains after 6 months of treatment
(129 cells/mm 3 versus ART-LINC 106 cells/mm 3) were
similar. This analysis involves a very large dataset involv-
ing many programmes in conflict affected environments
and thus provides important data supporting the effec-
tiveness of providing ART in these environments.
2. "Adherence to treatment is likely to be poor due to forced 
displacement and population mobility."
There is no evidence that, providing the drug supply is
well-managed, people will be any less adherent to ART in
conflict settings. Our experience is that people adhere
well [11], but treatment should be provided free of charge
given the negative impact of user fees on access to ser-
vices and adherence to ART [30]. Acute programme dis-
ruptions were uncommon and rarer than expected; the
only programme to face such disruption was Bukavu,
DRC, for 2 weeks in 2005[11]. Disruptions can occur even
in 'stable' settings, either due to unexpected conflict such
as in Kenya in 2008[31] or through drug ruptures second-
ary to mismanagement or financial limitations [32]. Thus
many of the practical measures used in these settings
could be applied in all HIV programmes and also to par-
ticular populations at higher risk of interruption such as
migrants and nomadic populations.
With the proliferation of access to treatment in stable
settings, leakage of drugs into the informal sector is inev-
itable even in conflict settings, and the absence of treat-
ment programmes forces people to look to these costly
and sub-standard sources. In such contexts provision of
treatment is also a form of harm reduction.
Populations in conflict and post-conflict settings can be
mobile. In Liberia, our patients would often cross the
borders into neighbouring Sierra Leone and Guinea seek-
ing health care or better conditions. Programmes need to
allow for population movement (Appendix 1). If popula-
tion movements are planned in advance, management
strategies can include the provision of 3-6 months of
ARVs for patients stable on treatment, or if medically sta-
ble, delaying initiation of ART until the patient arrives in
the new destination [15]. Simple, cheap, and readily avail-
a b l e  r e g i m e n s  m a y  be  p r e f e r r ed  t o  m o r e  c o m p l e x  a n d
expensive ones that may not be available elsewhere.
3. "Treatment should be life-long. People may be started on 
treatment, only to stop after 6 months or a year."
In resource-limited settings significant health benefits are
usually obtained within 6 months of starting ART; mor-
tality can be reduced by up to 78% [6], rates of opportu-
nistic infections reduced by 56%[33], and robust
immunological gains obtained[28]. We saw good survival
and immunological outcomes at 6 months. People also
became informed about their illness and the benefits of
treatment. This improved health and knowledge may
enable them to better manage their illness if treatment
stops, reduce the risk of them transmitting the virus by
a d a p t i n g  b e h a v i o u r ,  a n d  h e l p  t h e m  t o  p o t e n t i a l l y  s e e k
treatment elsewhere as it becomes increasingly available
in resource-limited settings [19].
Predictions of how long people will be able to take
treatment and what will happen in the future are rarely
possible. Where there is uncertainty people should be
given the chance of receiving treatment, but informed
patient consent should be obtained regarding risks, bene-
fits, and potential for interruption or cessation of ART.
However it is important to determine the minimum time
that treatment should be available to obtain benefit.
While absolute rules on this are difficult, we and others
feel that around 3-6 months on treatment should be seen
as a minimum [15].
4. "Stopping treatment will lead to resistance."
It is clear that while regular treatment interruptions do
promote resistance, the risk of developing resistance due
to a single stop of treatment is low. The risk is further
reduced if those taking an NNRTI-based regimen receive
a 1-week continuation of dual nucleoside reverse tran-O'Brien et al. Conflict and Health 2010, 4:12
http://www.conflictandhealth.com/content/4/1/12
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scriptase inhibitor (NRTI) therapy (ie AZT/3TC or D4T/
3TC; a 'washout' course) to cover the drug's longer half-
life [34], or, for those on a PI-based regimen, all drugs are
stopped together [35].
5. "Resources should be directed to other more important 
acute health priorities."
In high HIV prevalence areas many competing health pri-
orities such as malaria, diarrhoea, and tuberculosis occur
more frequently and have a higher mortality due to the
presence of underlying HIV. Addressing underlying HIV
substantially contributes to addressing these needs and
reduces their demands on medical services. In our expe-
rience, integration of HIV activities strengthened other
health activities such as the diagnosis and treatment of
tuberculosis and maternal and reproductive health by
sharing resources and improving laboratory services,
procurement, supply, and monitoring mechanisms. This
contributes to improving the health of all victims of con-
flict but also increases the likelihood of sustainability for
implemented activities [see Additional file 1, Table S1]
[12].
Nevertheless, there are certainly low HIV-prevalence
settings or especially difficult and unstable environments
where the potential benefits of introducing ART may not
justify the resources required. In some conflict-affected
areas such as Somalia, Darfur, and Sri Lanka, MSF-OCA
has not introduced HIV treatment activities (apart from
post-exposure prophylaxis) because of a lack of HIV-
related medical needs identified by field teams, often
compounded by potentially serious negative conse-
quences for those testing positive. A decision to provide
treatment should, like all health-care decisions, be made
on an informed and unprejudiced assessment of the
needs and priorities of the population and the feasibility
of an effective response.
6. "HIV programmes should be sustainable"
Continuation or handover of HIV programmes started in
a conflict-affected area, usually without prior HIV activi-
ties, can pose significant challenges. Our experience was
that an established and effectively running programme
was a catalyst to engage other actors, especially National
Aids Programmes and MoHs, to provide ART in the
region [12]. Despite the difficult conditions in which the
programmes were instituted, a handover partner was
found for all programmes that MSF-OCA closed [see
Additional file 1, Table S1]. All programmes were handed
over to MoH, sometimes with national or international
non-governmental organisations providing technical sup-
port, training, support to procurement and supply chan-
nels, and funding of key staff. For example, in Mindouli,
Republic of Congo, the National AIDS Programme
funded key staff involved in HIV activities and accredited
the hospital as an ART site [12]. Early integration with
existing MoH systems and structures and planning and
discussion with potential partners facilitated the process.
Identification and onsite training of key staff to remain in
the programme was vital.
Further challenges in conflict environments
Prevention of Mother to Child Transmission (PMTCT)
Despite the recognised importance of the intervention
and a strong desire to implement it by programme man-
agers, the initial inclusion of PMTCT was surprising diffi-
cult in many settings, usually due to the resistance of
health-care staff. Their concerns included perceived
potential negative consequences for women diagnosed
HIV-positive, the complexity of the intervention in envi-
ronments where programme disruption was possible, a
lack of understanding of its potential benefits, and lim-
ited staff experience in managing HIV. Nevertheless, HIV
transmission rates can be reduced by partial interven-
tions even if full ones are prevented by programme dis-
ruption [36]. Our experience was that with simplified
protocols and tools, quality education and counselling of
women and staff, and the provision of extra resources,
PMTCT activities were possible. Infant feeding was com-
plicated by the potential for programme interruption to
leave mothers who formula fed without infant feeding
options, and therefore exclusive breastfeeding with early
rapid weaning at 6-9 months was usually promoted, apart
from Angola where almost all women were offered and
adopted formula feeding.
Paediatric HIV care
Similarly to programmes in stable settings, the inclusion
of infants and children was limited. This was influenced
by difficulties diagnosing HIV in children, low clinician
confidence in clinical HIV paediatric care, and lack of
drugs in adapted formulations and fixed-dose combina-
tions [37]. Strategies targeting children, especially
orphans, and improved and adapted diagnostic tools and
medications are needed in these settings.
Conclusion
The primary benefit of introducing ART in conflict-
affected settings is the reduction of HIV-related morbid-
ity and mortality in affected populations, giving hope and
health to people slowly dying in environments character-
ized by loss, displacement, violence, and trauma. Addi-
tional benefits include strengthening of health systems
and increased morale of health staff and the community
when able to treat 'dying' patients and tackle HIV/AIDS.
In our experience this acts strongly to reduce HIV-related
stigma and discrimination further encouraging people to
seek HIV testing and care, allows prevention strategies to
be more openly discussed and implemented, and vitallyO'Brien et al. Conflict and Health 2010, 4:12
http://www.conflictandhealth.com/content/4/1/12
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improves the level of support for HIV-infected people by
family, health staff, and the community. It also leads to
increased HIV awareness and knowledge in the popula-
tion, and in many programmes to the creation of commu-
nity support and advocacy groups which can strengthen
the community's response to HIV and AIDS. Further-
more, the introduction of specific activities such as ART,
post-exposure prophylaxis, and PMTCT can have a sig-
nificant impact on HIV transmission, and thus may coun-
teract the risks of an increasing HIV epidemic in these
areas, especially in the post-conflict period.
Our experience in providing medical care to popula-
tions in conflict-affected areas, especially in sub-Saharan
Africa, shows that in many of these settings there are sig-
nificant HIV-related urgent health needs. This study has
reaffirmed previous reports that with commitment, sim-
plified treatment and monitoring, programmatic adapta-
tions for the conditions, and resources, HIV treatment
including ART can be feasibly and effectively provided in
conflict or post-conflict settings with many secondary
benefits. We hope our experience will encourage and help
others to include HIV treatment in their health interven-
tions where conflict and HIV-related health needs over-
lap.
Appendix 1: Practical measures for safe and 
effective HIV care in conflict settings
1. Design programmes to be resilient to disruption
• Simplify management and treatment protocols as 
much as possible
• Human resources planning: 1) a dedicated member 
of staff should be in charge of instability preparedness 
and training; 2) develop multiskilled staff and com-
munity group involvement to enable coverage if med-
ical staff are evacuated
• Halt initiation of patients on ART if acute instability 
occurs or is imminent. Non-essential services (eg 
general HIV education and testing) can be minimized 
and the frequency of follow-up and monitoring 
reduced
• Alternative site(s) for care delivery should be identi-
fied with community consultation taking into account 
routes likely to be used by the fleeing population.
• Alternative sources of care - identify programmes in 
neighbouring regions/countries that might be 
accessed by patients if migration occurred related to 
instability. Reciprocal arrangements for care should 
be agreed, and patients should carry treatment "pass-
ports" with information such as clinical illnesses, cur-
rent HIV drug regimens, adverse reactions, and 
relevant laboratory results.
• Communication networks (radio, mobile phones, 
and church and community groups) with staff and 
patients are essential during periods of instability.
• Inform all parties to the conflict and community 
leaders about the importance of maintaining the proj-
ect for their people, and ensure a clear image of inde-
pendence and neutrality for health care
2. Focus on adherence
• Patients must be educated and motivated to adhere 
to medications in the event of disruption. They 
should be advised not to conserve drugs, to take their 
drugs even if they have no food, and not to share 
medications or obtain drugs from sources where 
quality cannot be assured. Partners or a 'treatment 
buddy' can ensure adherence support if staff are evac-
uated.
3. Emergency drug stocks and forced treatment 
interruption
• Patients should have enough ARV drugs to cover a 
short disruption of drug delivery. We recommend a 
'runaway stock' of 1-3 months of treatment (including 
prophylaxis, especially cotrimoxazole) kept by the 
patient or given when disruption is anticipated. 
Patients should bring this to the clinic on each visit so 
that stock and expiry can be checked.
• If TB treatment has commenced, patients should be 
allotted enough medication to complete a full course; 
this should be stored in the clinic and given to the 
patient if instability is predicted. Patients should be 
educated on how to take their medications, with 
many of the same adherence rules in times of crisis as 
for ARVs plus information on managing a safe treat-
ment interruption by ceasing all TB drugs at once if 
unavoidable.
• Patients should be given clear information regarding 
conditions under which they should stop treatment 
and how to reduce risks associated with disruption. If 
a washout course (dual NRTI tail for 1 week) is 
required it should ideally be given immediately prior 
to instability, but can be given at the start of treatment 
in contexts where instability is likely, to be kept and 
taken if treatment disruption occurs.
4. Security of drug stocks
• Large amounts of drugs are a risk for looting. Stock 
should be locked securely in a discreet location. A 
buffer stock should be available, but it might be nec-
essary to have excess stock evacuated if looting is a 
risk. Large stocks should not be kept in high-risk 
sites. Dividing stock and storing it at different loca-
tions minimises the risk of losing all of it or of all 
stock being inaccessible for security reasons.
Consent
Written informed consent was obtained from the patient
for publication of this report and accompanying images.O'Brien et al. Conflict and Health 2010, 4:12
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A copy of the written consent is available for review by
the Editor-in-Chief of this journal.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DO'B conceived and wrote and researched the paper. SV helped design, write,
and research the paper. JG did statistical analyses. LS helped with research and
writing of the paper. TE helped with research and writing of the paper. KS
helped with research and writing of the paper. LF helped with research and
writing of the paper. CM helped with design, research and writing of the paper.
All authors read and approved the final manuscript.
Acknowledgements
We thank Robin Meldrum for assistance in finding photographs and designing 
the map. We would like to acknowledge all the staff of MSF and our counter-
parts in the described programmes whose hard work and commitment to pro-
viding HIV care to vulnerable conflict-affected populations is described in this 
manuscript.
Author Details
1Public Health Department, Médecins Sans Frontières, Amsterdam, 
Netherlands, 2Department of Infectious Diseases, Geelong Hospital, Geelong, 
Australia, 3Victorian Infectious Diseases Service, Royal Melbourne Hospital, 
Melbourne, Australia, 4Manson Unit, Médecins Sans Frontières, London, UK, 
5School of Child and Adolescent Health, Red Cross Childrens' Hospital, 
Capetown, South Africa and 6Te Kupenga Hauora Maori, Faculty of Medical and 
Health Sciences,University of Auckland, Auckland, New Zealand
References
1. Spiegel PB, Bennedsen AR, Claass J, Bruns L, Patterson N, Yiweza D, et al.: 
Prevalence of HIV infection in conflict-affected and displaced people in 
seven sub-Saharan African countries: a systematic review.  Lancet 2007, 
369(9580):2187-95.
2. HIV and Conflict: A Double Emergency. Save the Children.  London; 
2002. 
3. Joint United Nations Programme on HIV/AIDS (UNAIDS): Towards 
universal access: scaling up priority HIV/AIDS interventions in the 
health sector Geneva.  2007 [http://www.who.int/hiv/mediacentre/
universal_access_progress_report_en.pdf]. accessed July 2009
4. Chamla DD, Olu O, Wanyana J, Natseri N, Mukooyo E, Okware S, et al.: 
Geographical information system and access to HIV testing, treatment 
and prevention of mother-to-child transmission in conflict affected 
Northern Uganda.  Confl Health 2007, 1:12.
5. Shannon K, Kaida A, Rachlis B, Lloyd-Smith E, Gray G, Strathdee SA: 
Reconsidering the impact of conflict on HIV infection among women 
in the era of antiretroviral treatment scale-up in sub-Saharan Africa: a 
gender lens.  AIDS 2008, 22:1705-1707.
6. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, et al.: 
Mortality in HIV-infected Ugandan adults receiving antiretroviral 
treatment and survival of their HIV-uninfected children: a prospective 
cohort study.  Lancet 2008, 371(9614):752-9.
7. De Cock KM, Crowley SP, Lo YR, Granich RM, Williams BG: Preventing HIV 
transmission with antiretrovirals.  Bulletin of the World Health 
Organization 2009, 87:488-488.
8. Ellman T, Culbert H, Torres-Feced V: Treatment of AIDS in conflict-
affected settings: a failure of imagination.  Lancet 2005, 
365(9456):278-80.
9. Sphere humanitarian charter and minimum standards in disaster 
response  2004 [http://www.sphereproject.org/content/view/27/84]. 
Geneva Sphere Project accessed August 2009
10. Inter-Agency Standing Committee (IASC): Guidelines for HIV/AIDS 
interventions in emergency settings.  Geneva 2004.
11. Culbert H, Tu D, O'Brien DP, Ellman T, Mills C, Ford N, et al.: HIV treatment 
in a conflict setting: Outcomes and experiences from Bukav, 
Democratic Republic of the Congo.  PLoS Med 2007, 4(5):e129.
12. O'Brien DP, Mills C, Hamel C, Ford N, Pottie K: Universal access: the 
benefits and challenges in bringing integrated HIV care to isolated and 
conflict affected populations in the Republic of Congo.  Conflict and 
Health 2009, 3:1.
13. Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-
Olupot P, et al.: Clinical and immunological outcomes of a national 
paediatric cohort receiving combination antiretroviral therapy in 
Uganda.  AIDS 2008, 22(18):2493-9.
14. Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, Fernandes KA, et 
al.: Combination antiretroviral therapy in population affected by 
conflict: outcomes from large cohort in northern Uganda.  BMJ 2009, 
338:b201. doi: 10.1136/bmj.b201
15. Clinical Guidelines for ART management for displaced populations 
Southern Africa: Southern African HIV Clinicians Society/UNHCR.  2007 
[http://sahivsoc.org/index.php?option=com_docman&Itemid = 67]. 
accessed August 2009
16. World Health Organisation: Towards universal access: scaling-up priority 
HIV/AIDS interventions in the health sector: progress report 2008.  
Geneva 2008.
17. Consensus statement: WHO UNHCR, UNAIDS MSF and UNICEF 19-20 
September.  Geneva 2006.
18. Epidemiological fact sheets on HIV/AIDS   [http://www.who.int/hiv/
pub/epidemiology/facts/en/index.html]. Geneva: WHO (accessed August 
2009)
19. Country specific estimates on people receiving antiretroviral therapy 
2005 [xls 63 kb   [http://www.who.int/hiv/data/archive/en/index.html]. 
Geneva:WHO (accessed August 2009)
20. World Health Organisation: Guidance on provider-initiated HIV testing 
and counseling in health facilities.  Geneva; 2007. 
21. Klarkowski DB, Wazome JM, Lokuge KM, Shanks L, Mills CF, O'Brien DP: 
(2009) The Evaluation of a Rapid In Situ HIV Confirmation Test in a 
Programme with a High Failure Rate of the WHO HIV Two-Test 
Diagnostic Algorithm.  PLoS ONE 4(2):e4351.
22. World Health Organisation: Antiretroviral therapy for adults and 
adolescents in resource-limited settings: towards universal access.  
Geneva; 2006. 
23. Hehenkamp A, Hargreaves S: Tuberculosis treatment in complex 
emergencies: South Sudan.  Lancet 2003, 362:s30-31.
24. Reid T, van Engelgem I, Telfer B, Manzi M: Providing HIV care in the 
aftermath of Kenya's post-election violence Medecins Sans Frontieres' 
lessons learned January - March 2008.  Confl Health 2008, 2:15.
25. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L: Generic 
fixed-dose combination antiretroviral treatment in resource-poor 
settings: multicentric observational cohort.  AIDS 2006, 20(8):1163-9.
26. Ferradini L, Jeannin A, Pinoges L, et al.: Scaling up of highly active 
antiretroviral therapy in a rural district of Malawi: an effectiveness 
assessment.  Lancet 2006, 367:1335-1342.
27. Elema R, Mills C, Yun O, Ssonko C, Nyirongo N, Mtonga V, Zulu H, Tu D, 
O'Brien DP: Outcomes of a remote, decentralized health center-based 
HIV/AIDS antiretroviral program in Zambia, 2004-2007.  J Int Assoc 
Physicians AIDS Care 2009, 8(1):60-67.
28. Boulle A, Van Gustum G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, 
Ford N, Knight L, Osler M, Myers J, Goemaere E, Coetzee D, Maartens G: 
Seven-year experience of a primary care antiretroviral treatment 
programme in Khayelitsha, South Africa.  AIDS 2010, 24:563-572.
29. Antiretroviral Therapy in Lower Income Countries (ART-LINC) 
Collaboration and ART Cohort Collaboration (ART-CC) groups: Mortality 
of HIV-1-infected patients in the first year of antiretroviral therapy: 
comparison between low-income and high-income countries.  Lancet 
2006, 367:817-824.
Additional file 1 Table S1: Programme summaries and contextPro-
gramme contexts and settings.
Additional file 2 Table S2: Project data on HIV prevalence and patient 
numbers. Programme data and outcomes. Table S3: Baseline and outcome 
information on adult patients commenced on ART. Programme data and 
outcomes.
Received: 3 March 2010 Accepted: 17 June 2010 
Published: 17 June 2010
This article is available from: http://www.conflictandhealth.com/content/4/1/12 © 2010 O'Brien et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conflict and Health 2010, 4:12O'Brien et al. Conflict and Health 2010, 4:12
http://www.conflictandhealth.com/content/4/1/12
Page 9 of 9
30. Zachariah R, Van Engelgem I, Massaquoi M, Kocholla L, Manzi M, Suleh A, 
et al.: Payment for antiretroviral drugs is associated with a higher rate of 
patients lost to follow-up than those offered free-of-charge therapy in 
Nairobi, Kenya. Transactions of the Royal Society of Tropical Medicine 
and Hygiene (2008).  102:288-293.
31. Vreeman RC, Nyandiko WM, Sang E, Musick BS, Braitstein P, Wiehe SE: 
Impact of the Kenya post-election crisis on clinic attendance and 
medication adherence for HIV-infected children in western Kenya 
Confl Health.  2009, 3:5.
32. El-Khatib Z, Richter M: Free State? The moratorium's threat to patients' 
adherence and the development of drug-resistant HIV.  S Afr Med J 
2009:412-414.
33. Balkan S, O'Brien D, Humblet P, Pujades M, MSF AIDS Working Group: The 
Burden of OI in Adults Receiving ART in Resource-limited Settings in 
Médecins Sans Frontières-supported Projects 14th Conference of 
Retroviruses and Opportunistic Infections, Los Angeles.  2007. Abstract 
# 839
34. Chaix ML, Ekouevi DK, Rouet F, Tonwe-Gold B, Viho I, et al.: (2006) Low risk 
of nevirapine resistance mutations in the prevention of mother-to-
child transmission of HIV-1: Agence Nationale de Recherches sur le 
SIDA Ditrame Plus,.Abidjan, Cote d'Ivoire.  J Infect Dis 193:482-487.
35. Taylor S, Boffito M, Khoo S, Smit E, Back D: Stopping antiretroviral 
therapy.  AIDS 2007, 21:1673-1682.
36. Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, et al.: Field efficacy 
of zidovudine, lamivudine and single-dose nevirapine to prevent 
peripartum HIV transmission.  AIDS 2005, 19:309-318.
37. O'Brien DP, Sauvageot D, Zachariah R, Humblet P: In resource-limited 
settings good early outcomes can be achieved in children using adult 
fixed-dose combination antiretroviral therapy.  AIDS 2006, 20:1955-60.
doi: 10.1186/1752-1505-4-12
Cite this article as: O'Brien et al., Provision of antiretroviral treatment in con-
flict settings: the experience of Médecins Sans Frontières Conflict and Health 
2010, 4:12